Cargando…

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

BACKGROUND: Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data from the primary analysis of a phase 2 study of daratumumab monotherapy in relapse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Huiqiang, Zhu, Jun, Yao, Ming, Kim, Tae Min, Yoon, Dok Hyun, Cho, Seok-Goo, Eom, Hyeon Seok, Lim, Soon Thye, Yeh, Su-peng, Song, Yuqin, Kwong, Yok Lam, Kim, Jin Seok, Jin, Jie, Shi, Yuankai, Kim, HyeJin, Qing, Min, Zhou, Tianyuan, Gao, Grace, Dong, Zongqi, Qi, Ming, Kim, Won Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885403/ https://www.ncbi.nlm.nih.gov/pubmed/33588922 http://dx.doi.org/10.1186/s13045-020-01020-y

Ejemplares similares

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
por: Yoon, Dok Hyun, et al.
Publicado: (2020)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second
por: Kim, Jin-Hyo, et al.
Publicado: (2022)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
por: Byun, Ja Min, et al.
Publicado: (2022)

Treatment outcome of nasal natural killer/T-cell lymphoma
por: Lee, Hyun Jin, et al.
Publicado: (2011)

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
por: Yhim, Ho-Young, et al.
Publicado: (2020)

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
por: Kim, Seok Jin, et al.
Publicado: (2013)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study
por: Tan, Khee Ming, et al.
Publicado: (2019)

Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?
por: Kim, Seok Jin, et al.
Publicado: (2012)

Monotherapy in patients with type 2 diabetes mellitus
por: Rhee, Sang Youl, et al.
Publicado: (2017)

Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Rhee, Sang Youl, et al.
Publicado: (2017)

Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
por: Kim, Seok Jin, et al.
Publicado: (2018)

Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy
por: Chitimus, Diana Maria, et al.
Publicado: (2022)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma
por: Kim, Tae Hyung, et al.
Publicado: (2016)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Involving Skin Masquerading as Eczema
por: Kim, Ji Seok, et al.
Publicado: (2016)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas
por: Kim, Jin Ju, et al.
Publicado: (2023)

l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia
por: Jung, Ki Sun, et al.
Publicado: (2016)

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy
por: Kim, Yu Ri, et al.
Publicado: (2011)

Action Tremor Associated with Lamotrigine Monotherapy
por: Yang, Ji-Hye, et al.
Publicado: (2010)

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
por: Suzuki, Kenshi, et al.
Publicado: (2023)

Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study
por: Lee, Seul, et al.
Publicado: (2015)

Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies
por: Tse, Eric, et al.
Publicado: (2022)

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)
por: Yoon, Dok Hyun, et al.
Publicado: (2016)

Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study
por: Oh, Eun-Jee, et al.
Publicado: (2021)

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
por: Mustafa, Nurulhuda, et al.
Publicado: (2021)

Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T‐cell lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2018)

Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
por: Thangaraj, Jaya Lakshmi, et al.
Publicado: (2022)

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
por: Usmani, Saad Z., et al.
Publicado: (2018)

Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Shi, HyeJin, et al.
Publicado: (2019)

Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia
por: Yoon, Sang Eun, et al.
Publicado: (2021)

Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
por: Shin, Junghoon, et al.
Publicado: (2019)

Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement
por: Kim, Seon Young, et al.
Publicado: (2013)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
por: Mikhael, Joseph, et al.
Publicado: (2021)

Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
por: Shackleton, Louisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7le7v4ubp9duj32h8bnvetlni6